Roquefort Therapeutics plc (LON:ROQ)

Market Cap	1.51M -55.6%
Revenue (ttm)	n/a
Net Income	-3.36M
EPS	-0.22
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	507,197
Open	1.0600
Previous Close	1.0000
Day's Range	0.9500 - 1.0600
52-Week Range	0.9500 - 30.0000
Beta	-0.56
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 27, 2026

About Roquefort Therapeutics

As of March 27, 2026, Roquefort Therapeutics plc (LSE:ROQ) was acquired by Coiled Therapeutics Inc. in a reverse merger transaction. Roquefort Therapeutics plc, a material biotech company, engages in the development of medicines for the treatment of cancer. Its product portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines, which include Midkine antibodies with significance in vivo efficacy and toxicology studies, as well as orphan drug indication; Midkine RNA oligonucleotide therapeutics with novel anti-cancer gen...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2020
• Employees: 6
• Stock Exchange: London Stock Exchange
• Ticker Symbol: ROQ

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 26, 2026

Data Sources Report a data error